Multinationals Score Three Out Four New China Priority Reviews
Eight drugs from foreign multinationals, including Amgen’s Rapatha, Takeda’s Takecab, Sanofi’s Aubagio and UCB’s Cimzia, are among 12 products awarded priority new drug approval reviews in China under a scheme to speed up approvals and patient access that is also benefiting some domestic players.
You may also be interested in...
Takeda is selling its majority share in China biopharma joint venture Techpool to focus on its key growth areas in this market and raise cash ahead of the Shire acquisition, in a move that will also boost its former partner’s presence in manufacturing and critical care.
Coming out of the local integration with Baxter's spin-off Baxalta in China, Shire may have to face more uncertainties in the country despite erstwhile acquirer Takeda having a much larger presence there, while competition is also brewing for the merged company from rare disease heavyweights such as Roche and Biogen.
The latest developments in a US Congressional draft bill to curb Chinese biotech operations in the US is separating contract manufacturing and research from gene sequencing service providers, which may give China's major contract players reasons to breathe easy.